Glisten Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.42 M
- Company Age 15 Year, 9 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 1.54%
- Ebitda 26.20%
- Net Worth -28.08%
- Total Assets -0.04%
About Glisten Pharmaceuticals India
Glisten Pharmaceuticals India Private Limited (GPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 February 2010 and has a history of 15 years. Its registered office is in Delhi, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.42 M, as per Ministry of Corporate Affairs (MCA) records.
Radhika Tripathi and Krishan Pandey serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100DL2010PTC198563
-
Company No.
198563
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Feb 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Glisten Pharmaceuticals India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Radhika Tripathi
|
Director | 22-Aug-2022 | Current |
|
Krishan Pandey
|
Director | 01-Feb-2010 | Current |
Financial Performance of Glisten Pharmaceuticals India.
Glisten Pharmaceuticals India Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 1.54% increase in profit. The company's net worth observed a substantial decline by a decrease of 28.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glisten Pharmaceuticals India?
In 2017, Glisten Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Greencare Realty & Infratech Private LimitedRadhika Tripathi and Krishan Pandey are mutual person
-
Earthocare Projects Llp
Radhika Tripathi is a mutual person
-
Green Tasck Infratech Private Limited
Radhika Tripathi is a mutual person
-
Nexgen Maruti Infra Private Limited
Krishan Pandey is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glisten Pharmaceuticals India?
Unlock and access historical data on people associated with Glisten Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glisten Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glisten Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
